Another study revealed that tumor cell glycolysis reduces tumor cell sensitivity to cytotoxic T-cell killing and that GLUT1 inhibitors can enhance the efficacy of tumor immunotherapy by inhibiting tumor cell glycolysis [22]. Here, SLC2A1 is linked to neoplasm.